Secondary Macular Hole Closure With Sub-Tenon Triamcinolone Acetonide

Purpose: To evaluate the efficacy and safety of sub-Tenon triamcinolone acetonide in the management of secondary full-thickness macular holes after vitreoretinal surgeries or traumatic injury. Methods: This case series includes 3 patients with secondary macular holes. All patients were treated with 40 mg sub-Tenon triamcinolone acetonide injections for macular holes. Results: Postinjection, the macular holes closed in 2 months, 2 weeks, and 1 month, respectively. Vision improved in all cases. The third patient experienced a significant increase in intraocular pressure, effectively managed with topical medications. No recurrence was observed at follow-up. Conclusions: Sub-Tenon triamcinolone acetonide is a promising therapeutic option for the management of secondary macular holes less than 200 µm in diameter, demonstrating efficacy in promoting hole closure and improving visual outcomes.